Effect of HIV Infection and Menopause Status on Raltegravir Pharmacokinetics in the Blood and Genital Tract
暂无分享,去创建一个
A. Kashuba | N. White | K. Patterson | Amanda Jones | Heather M. A. Prince | Ruili Wang | M. Cottrell
[1] F. Aweeka,et al. Raltegravir Pharmacokinetics During Pregnancy , 2014, Journal of acquired immune deficiency syndromes.
[2] M. Baes,et al. Vaginal expression of efflux transporters and the potential impact on the disposition of microbicides in vitro and in rabbits. , 2014, Molecular pharmaceutics.
[3] M. Sobieszczyk,et al. A forgotten population: older adults with newly diagnosed HIV. , 2014, AIDS patient care and STDs.
[4] D. Kroetz,et al. Expression of six drug transporters in vaginal, cervical, and colorectal tissues: Implications for drug disposition in HIV prevention , 2014, Journal of clinical pharmacology.
[5] J. Lifson,et al. Persistence of Viral Reservoirs in Multiple Tissues after Antiretroviral Therapy Suppression in a Macaque RT-SHIV Model , 2013, PloS one.
[6] A. Kashuba,et al. Single and Multiple Dose Pharmacokinetics of Dolutegravir in the Genital Tract of HIV-Negative Women , 2013, Antiviral therapy.
[7] S. Poloyac,et al. Short communication: expression of transporters and metabolizing enzymes in the female lower genital tract: implications for microbicide research. , 2013, AIDS research and human retroviruses.
[8] H. Jono,et al. Role of P-glycoprotein in the efflux of raltegravir from human intestinal cells and CD4+ T-cells as an interaction target for anti-HIV agents. , 2013, Biochemical and biophysical research communications.
[9] N. Shaheen,et al. Differential penetration of raltegravir throughout gastrointestinal tissue: implications for eradication and cure , 2013, AIDS.
[10] M. Hudgens,et al. Raltegravir Pharmacokinetics in Treatment-Naive Patients Is Not Influenced by Race: Results from the Raltegravir Early Therapy in African-Americans Living with HIV (REAL) Study , 2012, Antimicrobial Agents and Chemotherapy.
[11] K. Mayer,et al. Highly active antiretroviral therapy does not completely suppress HIV in semen of sexually active HIV-infected men who have sex with men , 2012, AIDS.
[12] Michael Rayment,et al. Prevention of HIV-1 infection with early antiretroviral therapy , 2012, Journal of Family Planning and Reproductive Health Care.
[13] E. Clementi,et al. Inter- and intra-patient variability of raltegravir pharmacokinetics in HIV-1-infected subjects. , 2012, The Journal of antimicrobial chemotherapy.
[14] R. Tubiana,et al. Raltegravir Concentrations in the Genital Tract of HIV-1-Infected Women Treated with a Raltegravir-Containing Regimen (DIVA 01 Study) , 2011, Antimicrobial Agents and Chemotherapy.
[15] J. Hogan,et al. Genital tract HIV-1 RNA shedding among women with below detectable plasma viral load , 2010, AIDS.
[16] Ning Wang,et al. HIV Transmission Risk Among Serodiscordant Couples: A Retrospective Study of Former Plasma Donors in Henan, China , 2010, Journal of acquired immune deficiency syndromes.
[17] Lenine J P Liebenberg,et al. Persistence of Genital Tract T Cell Responses in HIV-Infected Women on Highly Active Antiretroviral Therapy , 2010, Journal of Virology.
[18] J. Yamamoto-Furusho,et al. High gene expression of MDR1 (ABCB1) is associated with medical treatment response and long-term remission in patients with ulcerative colitis. , 2010, Inflammatory bowel diseases.
[19] G. Jansen,et al. ABC drug transporters and immunity: novel therapeutic targets in autoimmunity and cancer , 2009, Journal of leukocyte biology.
[20] B. Damle,et al. Maraviroc Concentrates in the Cervicovaginal Fluid and Vaginal Tissue of HIV-Negative Women , 2009, Journal of acquired immune deficiency syndromes.
[21] A. Kashuba,et al. An accurate and precise high-performance liquid chromatography method for the rapid quantification of the novel HIV integrase inhibitor raltegravir in human blood plasma after solid phase extraction. , 2008, Analytica chimica acta.
[22] Myron S. Cohen,et al. Antiretroviral drug exposure in the female genital tract: implications for oral pre- and post-exposure prophylaxis , 2007, AIDS.
[23] C. Kovacs,et al. Antiretroviral Activity, Pharmacokinetics, and Tolerability of MK-0518, a Novel Inhibitor of HIV-1 Integrase, Dosed As Monotherapy for 10 Days in Treatment-Naive HIV-1-Infected Individuals , 2006, Journal of acquired immune deficiency syndromes.
[24] S. Cu-Uvin,et al. Protease Inhibitor and Nonnucleoside Reverse Transcriptase Inhibitor Concentrations in the Genital Tract of HIV-1-Infected Women , 2004, Journal of acquired immune deficiency syndromes.
[25] J. Baeten,et al. Use of hormonal contraceptives and risk of HIV-1 transmission : a prospective cohort study , 2011 .
[26] A. Kashuba,et al. Quantifying the HIV-1 integrase inhibitor raltegravir in female genital tract secretions using high-performance liquid chromatography with ultraviolet detection. , 2010, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[27] S. Krähenbühl,et al. Regulation of BCRP (ABCG2) and P-Glycoprotein (ABCB1) by Cytokines in a Model of the Human Blood–Brain Barrier , 2009, Cellular and Molecular Neurobiology.
[28] E. Capparelli,et al. Pharmacokinetics of Antiretrovirals in Pregnant Women , 2004, Clinical pharmacokinetics.